Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment

SIMPLE SUMMARY: Multiple Myeloma (MM) is the second most common hematological malignancy in the world. The current two US Food and Drug Administration (FDA)-approved anti-BCMA chimeric antigen receptor (CAR)-T cells therapies for MM treatment rely on patients’ own peripheral blood T cells and can on...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Zhicheng, Zhu, Sumin, Zhang, Xi, Gong, Zhiyuan, Wang, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913487/
https://www.ncbi.nlm.nih.gov/pubmed/36765526
http://dx.doi.org/10.3390/cancers15030567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913487/
https://www.ncbi.nlm.nih.gov/pubmed/36765526
http://dx.doi.org/10.3390/cancers15030567

Ejemplares similares